Ischemia Reperfusion Injury – Pipeline Review, H2 2019

Global Markets Direct’s, ‘Ischemia Reperfusion Injury – Pipeline Review, H2 2019’, provides an overview of the Ischemia Reperfusion Injury pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Ischemia Reperfusion Injury, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ischemia Reperfusion Injury and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Ischemia Reperfusion Injury

– The report reviews pipeline therapeutics for Ischemia Reperfusion Injury by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Ischemia Reperfusion Injury therapeutics and enlists all their major and minor projects

– The report assesses Ischemia Reperfusion Injury therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Ischemia Reperfusion Injury

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Ischemia Reperfusion Injury

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Ischemia Reperfusion Injury pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Akashi Therapeutics Inc

Argenx SE

Balmes Transplantation SAS

Bolder Biotechnology Inc

Catalyst Biosciences Inc

Celdara Medical LLC

Cellmid Ltd

CFM Pharma Holding BV

Corline Biomedical AB

Cypralis Ltd

Gilead Sciences Inc

Glucox Biotech AB

Ischemix Inc

Lee's Pharmaceutical Holdings Ltd

LG Chem Ltd

Mallinckrodt Plc

Orion Corp

Pfizer Inc

Radikal Therapeutics Inc

Reata Pharmaceuticals Inc

SBI Pharmaceuticals Co Ltd

Stealth BioTherapeutics Corp

United Therapeutics Corp

Table of Contents

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Ischemia Reperfusion Injury ”“ Overview

Ischemia Reperfusion Injury ”“ Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Ischemia Reperfusion Injury ”“ Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Ischemia Reperfusion Injury ”“ Companies Involved in Therapeutics Development

Akashi Therapeutics Inc

Argenx SE

Balmes Transplantation SAS

Bolder Biotechnology Inc

Catalyst Biosciences Inc

Celdara Medical LLC

Cellmid Ltd

CFM Pharma Holding BV

Corline Biomedical AB

Cypralis Ltd

Gilead Sciences Inc

Glucox Biotech AB

Ischemix Inc

Lee's Pharmaceutical Holdings Ltd

LG Chem Ltd

Mallinckrodt Plc

Orion Corp

Pfizer Inc

Radikal Therapeutics Inc

Reata Pharmaceuticals Inc

SBI Pharmaceuticals Co Ltd

Stealth BioTherapeutics Corp

United Therapeutics Corp

Ischemia Reperfusion Injury ”“ Drug Profiles

aminolevulinic acid hydrochloride ”“ Drug Profile

ANV-6L15 ”“ Drug Profile

AP-39 ”“ Drug Profile

APP-103 ”“ Drug Profile

ARGX-117 ”“ Drug Profile

AT-300 ”“ Drug Profile

BBT-059 ”“ Drug Profile

BT-0213 ”“ Drug Profile

BT-0301 ”“ Drug Profile

BT-0402 ”“ Drug Profile

CAB-101 ”“ Drug Profile

cannabidiol ”“ Drug Profile

CB-2782 ”“ Drug Profile

CC-4066 ”“ Drug Profile

cerium oxide ”“ Drug Profile

CMX-2043 ”“ Drug Profile

cyclocreatine phosphate ”“ Drug Profile

Cymac-001 ”“ Drug Profile

DH-404 ”“ Drug Profile

Fusion Protein to Antagonize EPHA4 for CNS Disorders, Cardiovascular Diseases and Sepsis ”“ Drug Profile

IL-233 ”“ Drug Profile

KN-93 ”“ Drug Profile

LC-280126 ”“ Drug Profile

MG-53 ”“ Drug Profile

Monoclonal Antibodies to Inhibit MMP-8 for Ischemia Reperfusion Injury and Shock ”“ Drug Profile

Monoclonal Antibody to Inhibit IL-16 for Renal Ischemia Reperfusion Injury ”“ Drug Profile

MP-3964 ”“ Drug Profile

NLS-3 ”“ Drug Profile

NP-202 ”“ Drug Profile

Oligonucleotide for Cardiovascular Diseases and Oncology ”“ Drug Profile

ORM-10103 ”“ Drug Profile

PEG-HCC ”“ Drug Profile

Peptides to Modulate SRC Family Kinase for Ischemia Reperfusion Injury ”“ Drug Profile

R-100 ”“ Drug Profile

R-190 ”“ Drug Profile

Recombinant Enzymes to Activate ALDH2 for Alcohol Poisoning, Ischemia Reperfusion Injury and Metabolic Disorders ”“ Drug Profile

Recombinant Protein for Acute Kidney Injury, Acute Radiation Syndrome, Inflammatory Bowel Disease, Ischemic Organ Injury and Sepsis ”“ Drug Profile

Recombinant Protein to Agonize Robo1 for Ischemia Reperfusion Injury and Thrombosis ”“ Drug Profile

Recombinant Proteins for Ischemia Reperfusion Injury and Hypoxia ”“ Drug Profile

Recombinant Proteins to Agonize PTCH1 for Ischemia Reperfusion Injury ”“ Drug Profile

regadenoson ”“ Drug Profile

Remodulin ”“ Drug Profile

Renaparin ”“ Drug Profile

SBT-20 ”“ Drug Profile

SBT-272 ”“ Drug Profile

sirolimus ”“ Drug Profile

Small Molecule to Agonize FPR1 and FPR2 for Ischemia Reperfusion Injury ”“ Drug Profile

Small Molecules for Ischemia Reperfusion Injury ”“ Drug Profile

Small Molecules for Ischemia Reperfusion Injury and Neuroinflammation ”“ Drug Profile

Small Molecules for Metastatic Liver Cancer and Hepatic Ischemia Reperfusion Injury ”“ Drug Profile

Small Molecules for Myocardial Ischemia Reperfusion Injury ”“ Drug Profile

Small Molecules to Activate Protein Kinase B for Ischemia Reperfusion Injury ”“ Drug Profile

Small Molecules to Inhibit CRP for Ischemic Reperfusion Injury ”“ Drug Profile

Small Molecules to Inhibit NOX4 and NOX2 for Ischemia Reperfusion Injury ”“ Drug Profile

Synthetic Peptide for Ischemia Reperfusion Injury ”“ Drug Profile

Synthetic Peptides for Cardiovascular Disorders, Immunology and Oncology ”“ Drug Profile

Ti-061 ”“ Drug Profile

tiomolibdate diammonium ”“ Drug Profile

tiprelestat ”“ Drug Profile

tofacitinib citrate ”“ Drug Profile

UWA-TAT ”“ Drug Profile

Vanadis-01 ”“ Drug Profile

Vanadis-03 ”“ Drug Profile

VCP-746 ”“ Drug Profile

YQ-23 ”“ Drug Profile

ZK-001 ”“ Drug Profile

Ischemia Reperfusion Injury ”“ Dormant Projects

Ischemia Reperfusion Injury ”“ Discontinued Products

Ischemia Reperfusion Injury ”“ Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Ischemia Reperfusion Injury, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Products under Development by Universities/Institutes, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Ischemia Reperfusion Injury ”“ Pipeline by Akashi Therapeutics Inc, H2 2019

Ischemia Reperfusion Injury ”“ Pipeline by Argenx SE, H2 2019

Ischemia Reperfusion Injury ”“ Pipeline by Balmes Transplantation SAS, H2 2019

Ischemia Reperfusion Injury ”“ Pipeline by Bolder Biotechnology Inc, H2 2019

Ischemia Reperfusion Injury ”“ Pipeline by Catalyst Biosciences Inc, H2 2019

Ischemia Reperfusion Injury ”“ Pipeline by Celdara Medical LLC, H2 2019

Ischemia Reperfusion Injury ”“ Pipeline by Cellmid Ltd, H2 2019

Ischemia Reperfusion Injury ”“ Pipeline by CFM Pharma Holding BV, H2 2019

Ischemia Reperfusion Injury ”“ Pipeline by Corline Biomedical AB, H2 2019

Ischemia Reperfusion Injury ”“ Pipeline by Cypralis Ltd, H2 2019

Ischemia Reperfusion Injury ”“ Pipeline by Gilead Sciences Inc, H2 2019

Ischemia Reperfusion Injury ”“ Pipeline by Glucox Biotech AB, H2 2019

Ischemia Reperfusion Injury ”“ Pipeline by Ischemix Inc, H2 2019

Ischemia Reperfusion Injury ”“ Pipeline by Lee's Pharmaceutical Holdings Ltd, H2 2019

Ischemia Reperfusion Injury ”“ Pipeline by LG Chem Ltd, H2 2019

Ischemia Reperfusion Injury ”“ Pipeline by Mallinckrodt Plc, H2 2019

Ischemia Reperfusion Injury ”“ Pipeline by Orion Corp, H2 2019

Ischemia Reperfusion Injury ”“ Pipeline by Pfizer Inc, H2 2019

Ischemia Reperfusion Injury ”“ Pipeline by Radikal Therapeutics Inc, H2 2019

Ischemia Reperfusion Injury ”“ Pipeline by Reata Pharmaceuticals Inc, H2 2019

Ischemia Reperfusion Injury ”“ Pipeline by SBI Pharmaceuticals Co Ltd, H2 2019

Ischemia Reperfusion Injury ”“ Pipeline by Stealth BioTherapeutics Corp, H2 2019

Ischemia Reperfusion Injury ”“ Pipeline by United Therapeutics Corp, H2 2019

Ischemia Reperfusion Injury ”“ Dormant Projects, H2 2019

Ischemia Reperfusion Injury ”“ Discontinued Products, H2 2019

List of Figures

List of Figures

Number of Products under Development for Ischemia Reperfusion Injury, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Number of Products by Top 10 Targets, H2 2019

Number of Products by Stage and Top 10 Targets, H2 2019

Number of Products by Top 10 Mechanism of Actions, H2 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports